Matrix metalloproteinase-9 regulates TNF-α and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis

Experimental Neurology

Volumn 205, Issue 1, 2007, Pages 74-81

  Kiaei, Mahmoud ^a   Kipiani, Khatuna ^a   Calingasan, Noel Y ^a   Wille, Elizabeth ^a   Chen, Junyu ^a   Heissig, Beate ^a   Rafii, Shahin ^a   Lorenzl, Stefan ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ALS; Fas ligand; MMP 9; Motor neuron disease; Mutant SOD1; TNF

Indexed keywords

FAS LIGAND; GELATINASE B; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; ENZYME DEFICIENCY; FAMILIAL DISEASE; FEMALE; GENE CONTROL; GLIA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIFESPAN; LUMBAR SPINAL CORD; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAM PROTEINS; ALANINE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; FAS LIGAND PROTEIN; GLYCINE; HUMANS; IMMUNOLOGIC TECHNIQUES; LONGEVITY; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MUTATION; NERVOUS SYSTEM; NEUROGLIA; NEURONS; STAINING AND LABELING; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247276120     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.01.036     Document Type: Article

References (39)

1. 2 in CSF from ALS patients. Neurology 58 (2002) 1277-1279
2. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
3. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., and Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport 11 (2000) 3419-3422
4. Copin J.C., Goodyear M.C., Gidday J.M., Shah A.R., Gascon E., Dayer A., Morel D.M., and Gasche Y. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur. J. Neurosci. 22 (2005) 1597-1608
5. Cunningham L.A., Wetzel M., and Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50 (2005) 329-339
6. Demestre M., Orth M., Wells G.M., Gearing A.J., Hughes R.A., and Gregson N.A. Characterization of matrix metalloproteinases in denervated muscle. Neuropathol. Appl. Neurobiol. 31 (2005) 545-555
7. Dewil M., Schurmans C., Starckx S., Opdenakker G., Van Den Bosch L., and Robberecht W. Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. NeuroReport 16 (2005) 321-324
8. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., and Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104 (1999) 1507-1515
9. Ennis B.W., and Matrisian L.M. Matrix degrading metalloproteinases. J. Neuro-Oncol. 18 (1994) 105-109
10. Fujisawa K., Miyamoto Y., and Nagayama M. Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa. J. Oral Pathol. Med. 32 (2003) 358-366
11. Gasche Y., Soccal P.M., Kanemitsu M., and Copin J.C. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front. Biosci. 11 (2006) 1289-1301
12. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J.M., Crimmin M., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J. Leukocyte Biol. 57 (1995) 774-777
13. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., and Lipton S.A. S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297 (2002) 1186-1190
14. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., and Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182 (1995) 1777-1783
15. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
16. Kiaei M., Kipiani K., Petri S., Choi D.K., Chen J., Calingasan N.Y., and Beal M.F. Integrative role of cPLA with COX-2 and the effect of non-steroidal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 93 (2005) 403-411
17. Kiaei M., Kipiani K., Petri S., Chen J., Calingasan N.Y., and Beal M.F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. (2005) 246-254
18. Kiaei M., Petri S., Kipiani K., Gardian G., Choi D.K., Chen J., Calingasan N.Y., Schafer P., Muller G.W., Stewart C., Hensley K., and Beal M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 26 (2006) 2467-2473
19. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218 (1994) 325-329
20. Kwong J.Q., Beal M.F., and Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 97 (2006) 1659-1675
21. Lee S.R., Tsuji K., and Lo E.H. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. 24 (2004) 671-678
22. Lim G.P., Backstrom J.R., Cullen M.J., Miller C.A., Atkinson R.D., and Tokes Z.A. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J. Neurochem. 67 (1996) 251-259
23. Lorenzl S., De Pasquale G., Segal A.Z., and Beal M.F. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 34 (2003) e37-e38 (author reply e37-38)
24. Lorenzl S., Albers D.S., LeWitt P.A., Chirichigno J.W., Hilgenberg S.L., Cudkowicz M.E., and Beal M.F. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 207 (2003) 71-76
25. Lorenzl S., Albers D.S., Relkin N., Ngyuen T., Hilgenberg S.L., Chirichigno J., Cudkowicz M.E., and Beal M.F. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 43 (2003) 191-196
26. Lorenzl S., Narr S., Angele B., Krell H.W., Gregorio J., Kiaei M., Pfister H.W., and Beal M.F. The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp. Neurol. 200 1 (2006) 166-171
27. Ludolph A.C. Matrix metalloproteinases - a conceptional alternative for disease-modifying strategies in ALS/MND?. Exp. Neurol. 201 2 (2006) 277-280
28. McGeehan G.M., Becherer J.D., Bast Jr. R.C., Boyer C.M., Champion B., Connolly K.M., Conway J.G., Furdon P., Karp S., Kidao S., et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 370 (1994) 558-561
29. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Otten-Evans C., Greenstreet T., Weerawarna K., et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370 (1994) 218-220
30. Pasinelli P., Borchelt D.R., Houseweart M.K., Cleveland D.W., and Brown Jr. R.H. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15763-15768
31. Pasinelli P., Houseweart M.K., Brown Jr. R.H., and Cleveland D.W. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13901-13906
32. Pasinelli P., Belford M.E., Lennon N., Bacskai B.J., Hyman B.T., Trotti D., and Brown Jr. R.H. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43 (2004) 19-30
33. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., and Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22 (2006) 40-49
34. Schoser B.G., and Blottner D. Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. NeuroReport 10 (1999) 2795-2797
35. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
36. Vaday G.G., Schor H., Rahat M.A., Lahat N., and Lider O. Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J. Leukocyte Biol. 69 (2001) 613-621
37. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., and Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93 (1998) 411-422
38. Wooley C.M., Sher R.B., Kale A., Frankel W.N., Cox G.A., and Seburn K.L. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32 (2005) 43-50
39. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev., Neurosci. 2 (2001) 502-511